200 related articles for article (PubMed ID: 29211298)
21. Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Walterhouse DO; Pappo AS; Meza JL; Breneman JC; Hayes-Jordan A; Parham DM; Cripe TP; Anderson JR; Meyer WH; Hawkins DS
Cancer; 2017 Jun; 123(12):2368-2375. PubMed ID: 28211936
[TBL] [Abstract][Full Text] [Related]
22. Prognostic Factors and Treatment Outcomes of Adult Patients With Rhabdomyosarcoma After Multimodality Treatment.
Liu YT; Wang CW; Hong RL; Kuo SH
Anticancer Res; 2019 Mar; 39(3):1355-1364. PubMed ID: 30842169
[TBL] [Abstract][Full Text] [Related]
23. Paratesticular rhabdomyosarcoma in children and adolescents-Outcome and patterns of relapse when utilizing a nonsurgical strategy for lymph node staging: Report from the International Society of Paediatric Oncology (SIOP) Malignant Mesenchymal Tumour 89 and 95 studies.
Rogers T; Minard-Colin V; Cozic N; Jenney M; Merks JHM; Gallego S; Devalck C; Gaze MN; Kelsey A; Oberlin O; Stevens M; Spicer RD; Bergeron C; Martelli H
Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28205365
[TBL] [Abstract][Full Text] [Related]
24. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease.
Crist WM; Anderson JR; Meza JL; Fryer C; Raney RB; Ruymann FB; Breneman J; Qualman SJ; Wiener E; Wharam M; Lobe T; Webber B; Maurer HM; Donaldson SS
J Clin Oncol; 2001 Jun; 19(12):3091-102. PubMed ID: 11408506
[TBL] [Abstract][Full Text] [Related]
25. Clinical outcomes of pediatric patients with newly diagnosed rhabdomyosarcoma treated by two consecutive protocols - A single institution report in Taiwan.
Chou SW; Chang HH; Lu MY; Yang YL; Lin DT; Lin KH; Jou ST
J Formos Med Assoc; 2019 Jan; 118(1 Pt 2):332-340. PubMed ID: 29903549
[TBL] [Abstract][Full Text] [Related]
26. Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study.
Oberlin O; Rey A; Sanchez de Toledo J; Martelli H; Jenney ME; Scopinaro M; Bergeron C; Merks JH; Bouvet N; Ellershaw C; Kelsey A; Spooner D; Stevens MC
J Clin Oncol; 2012 Jul; 30(20):2457-65. PubMed ID: 22665534
[TBL] [Abstract][Full Text] [Related]
27. Perianal/perineal rhabdomyosarcoma: Results of the SIOP MMT 95, Italian RMS 96, and EpSSG RMS 2005 studies.
Rogers T; Zanetti I; Coppadoro B; Martelli H; Jenney M; Minard-Colin V; Terwisscha van Scheltinga SEJ; Skerritt C; Fajardo RD; Guérin F; Kelsey A; Merks JHM; Mandeville H; Guillén G; Glosli H; De Corti F; Bisogno G
Pediatr Blood Cancer; 2022 Sep; 69(9):e29739. PubMed ID: 35460336
[TBL] [Abstract][Full Text] [Related]
28. Improved outcome for patients with middle ear rhabdomyosarcoma: a children's oncology group study.
Hawkins DS; Anderson JR; Paidas CN; Wharam MD; Qualman SJ; Pappo AS; Scott Baker K; Crist WM
J Clin Oncol; 2001 Jun; 19(12):3073-9. PubMed ID: 11408504
[TBL] [Abstract][Full Text] [Related]
29. Treatment and outcome of patients with localized intrathoracic and chest wall rhabdomyosarcoma: a report of the Cooperative Weichteilsarkom Studiengruppe (CWS).
Fuchs J; Urla C; Sparber-Sauer M; Schuck A; Leuschner I; Klingebiel T; Blumenstock G; Seitz G; Koscielniak E
J Cancer Res Clin Oncol; 2018 May; 144(5):925-934. PubMed ID: 29464349
[TBL] [Abstract][Full Text] [Related]
30. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IV.
Breneman JC; Lyden E; Pappo AS; Link MP; Anderson JR; Parham DM; Qualman SJ; Wharam MD; Donaldson SS; Maurer HM; Meyer WH; Baker KS; Paidas CN; Crist WM
J Clin Oncol; 2003 Jan; 21(1):78-84. PubMed ID: 12506174
[TBL] [Abstract][Full Text] [Related]
31. Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma--a report from the IRSG.
Donaldson SS; Meza J; Breneman JC; Crist WM; Laurie F; Qualman SJ; Wharam M;
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(3):718-28. PubMed ID: 11597814
[TBL] [Abstract][Full Text] [Related]
32. Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology--SIOP Malignant Mesenchymal Tumor 89.
Stevens MC; Rey A; Bouvet N; Ellershaw C; Flamant F; Habrand JL; Marsden HB; Martelli H; Sanchez de Toledo J; Spicer RD; Spooner D; Terrier-Lacombe MJ; van Unnik A; Oberlin O
J Clin Oncol; 2005 Apr; 23(12):2618-28. PubMed ID: 15728225
[TBL] [Abstract][Full Text] [Related]
33. Prognostic factors of alveolar rhabdomyosarcoma in childhood. An International Society of Pediatric Oncology study.
Reboul-Marty J; Quintana E; Mosseri V; Flamant F; Asselain B; Rodary C; Zucker JM
Cancer; 1991 Aug; 68(3):493-8. PubMed ID: 2065269
[TBL] [Abstract][Full Text] [Related]
34. The prognostic value of early radiographic response in children and adolescents with embryonal rhabdomyosarcoma stage IV, metastases confined to the lungs: A report from the Cooperative Weichteilsarkom Studiengruppe (CWS).
Sparber-Sauer M; von Kalle T; Seitz G; Dantonello T; Scheer M; Münter M; Fuchs J; Ladenstein R; Bielack SS; Klingebiel T; Koscielniak E;
Pediatr Blood Cancer; 2017 Oct; 64(10):. PubMed ID: 28306214
[TBL] [Abstract][Full Text] [Related]
35. Sparing strategy does not compromise prognosis in pediatric localized synovial sarcoma: experience of the International Society of Pediatric Oncology, Malignant Mesenchymal Tumors (SIOP-MMT) Working Group.
Orbach D; Mc Dowell H; Rey A; Bouvet N; Kelsey A; Stevens MC
Pediatr Blood Cancer; 2011 Dec; 57(7):1130-6. PubMed ID: 21495161
[TBL] [Abstract][Full Text] [Related]
36. Conservative treatment for girls with nonmetastatic rhabdomyosarcoma of the genital tract: A report from the Study Committee of the International Society of Pediatric Oncology.
Martelli H; Oberlin O; Rey A; Godzinski J; Spicer RD; Bouvet N; Haie-Meder C; Terrier-Lacombe MJ; Sanchez de Toledo J; Spooner D; Sommelet D; Flamant F; Stevens MC
J Clin Oncol; 1999 Jul; 17(7):2117-22. PubMed ID: 10561266
[TBL] [Abstract][Full Text] [Related]
37. European intergroup studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors.
Carli M; Colombatti R; Oberlin O; Bisogno G; Treuner J; Koscielniak E; Tridello G; Garaventa A; Pinkerton R; Stevens M
J Clin Oncol; 2004 Dec; 22(23):4787-94. PubMed ID: 15570080
[TBL] [Abstract][Full Text] [Related]
38. Does aggressive local treatment have an impact on survival in children with metastatic rhabdomyosarcoma?
Ben Arush M; Minard-Colin V; Mosseri V; Defachelles AS; Bergeron C; Algret N; Fasola S; André N; Thebaud E; Corradini N; Bernier V; Martelli H; Ranchère D; Orbach D
Eur J Cancer; 2015 Jan; 51(2):193-201. PubMed ID: 25471261
[TBL] [Abstract][Full Text] [Related]
39. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
[TBL] [Abstract][Full Text] [Related]
40. Tumour volume reduction after neoadjuvant chemotherapy impacts outcome in localised embryonal rhabdomyosarcoma.
Dantonello TM; Stark M; Timmermann B; Fuchs J; Selle B; Linderkamp C; Handgretinger R; Hagen R; Feuchtgruber S; Kube S; Kosztyla D; Kazanowska B; Ladenstein R; Niggli F; Ljungman G; Bielack SS; Klingebiel T; Koscielniak E;
Pediatr Blood Cancer; 2015 Jan; 62(1):16-23. PubMed ID: 25263634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
